Xiaofeng Liang

Xiaofeng Liang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2021 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
HYHeya Yi
Heya Yi
YYYuan Yang
Yuan Yang
LZLi Zhang
Li Zhang
MZMuli Zhang
Muli Zhang
QWQing Wang
Qing Wang
LFLuzhao Feng
Luzhao Feng
To understand influenza vaccination and its correlates among health-careworkers (HCWs) during the 2019/2020 season in China, we used a self-administeredelectronic questionnaire to collect information on demographics, occupational characteristics, influenza vaccination status and access to free vaccination on the “Breath Circles”, a Chinese media platform for respiratory medical professionals. The reported influenza vaccine coverage among HCWs during this season was 67%, with more HCWs in a workplace with free vaccination than those with no free vaccination (79% vs.34%,p < .001). The influenza vaccine coverage among HCWs who were required or encouraged to get vaccinated by the workplace was significantly higher than that without any intervention measures (80% & 70 vs.39%,p < .001). The vaccine coverage in the workplaces with free and required vaccination simultaneously was highest compared to that with neither free vaccination nor any intervention measures (OR = 14.86, 95% CI: 10.93–20.20). The influenza vaccination coverage of HCWs in high-riskdepartments was significantly higher than that of other departments (70% vs.58%,p =.023). HCWs’ vaccine coverage was related to personal opinions and attitudes toward influenza or influenza vaccines, as well as other constraints such as availability of influenza vaccines, workplace regulations, and access to free vaccines.

1 May 2015 in Vaccine
Verified
Journal Article
Closed access
FWFeng Wang
Feng Wang
LSLiping Shen
Liping Shen
FCFuqiang Cui
Fuqiang Cui
SZShuang Zhang
Shuang Zhang
HZHui Zheng
Hui Zheng
SBShengli Bi
Shengli Bi

21 July 2022 in IEEE Transactions on Medical Imaging
Verified
Journal Article
Closed access
GJGuang Jia
Guang Jia
LHLiyu Huang
Liyu Huang
ZWZe Wang
Ze Wang
XLXiaofeng Liang
Xiaofeng Liang
YZYu Zhang
Yu Zhang
JTJie Tian
Jie Tian
Magnetic particle imaging (MPI) is a radiation-free vessel- and target-imaging modality that can sensitively detect nanoparticles. A static magnetic gradient field, referred to as a selection field, is required in MPI to provide a field-free region (FFR) for spatial encoding. The image resolution of MPI is closely related to the size of the FFR, which is determined by the selection field gradient amplitude. Because of the limitations of existing gradient coil hardware, the image resolution of MPI cannot satisfy the clinical requirements of human in vivo imaging. Pulsed excitation has been confirmed to improve the image resolution of MPI by breaking down the ’relaxation wall.’ This work proposes the use of a pulsed waveform magnetic gradient from magnetic resonance imaging to further improve the image resolution of MPI. Through alignment of the gradient direction along the field-free line (FFL), each location on the FFL is able to have a unique excitation field strength that generates a specific relaxation-induced decay signal. Through excitation of nanoparticles on the FFL with many gradient profiles, a high-resolution, one-dimensional (1D) image can be reconstructed on the FFL. For larger magnetic nanoparticles, simulation results revealed that a pulsed excitation field with a greater flat portion generates a 1D bar pattern phantom image with a higher correlation and spatial resolution. With parallel FFL and gradient coil movements, high-resolution, two-dimensional (2D) Shepp–Logan phantom and brain vessel maps were reconstructed through repetition of the spatially resolved measurement of magnetic nanoparticles on the FFL.

9 June 2023 in Medical Physics
Verified
Journal Article
Closed access
XFXin Feng
Xin Feng
GJGuang Jia
Guang Jia
JPJiaming Peng
Jiaming Peng
LHLiyu Huang
Liyu Huang
XLXiaofeng Liang
Xiaofeng Liang
JTJie Tian
Jie Tian

1 April 2021 in Vaccine
Verified
Journal Article
Closed access
TYTian Yao
Tian Yao
ZSZhihong Shao
Zhihong Shao
LWLina Wu
Lina Wu
SDShuang Dong
Shuang Dong
LGLinying Gao
Linying Gao
SWSuping Wang
Suping Wang

21 August 2017 in Expert Review of Vaccines
Verified
Journal Article
Closed access
YFYongliang Feng
Yongliang Feng
XSXiaohong Shi
Xiaohong Shi
JSJing Shi
Jing Shi
LGLinying Gao
Linying Gao
GLGuangming Liu
Guangming Liu
SWSuping Wang
Suping Wang
Background: To evaluate the immunogenicity, antibody persistence, and safety of the 60 µg hepatitis B vaccine in hemodialysis patients in China. Methods: We conducted a multicenter, randomized, double-blind, parallel-controlled trial including 352 hemodialysis patients who were centrally randomized in a ratio of 1:1 to receive a 20 µg (IM20 group) or 60 µg (IM60 group) recombinant hepatitis B vaccine at months 0, 1, and 6. Results: The vaccine-elicited antibody responses peaked at month 7, and declined at month 12. At month 7, the IM60 group had stronger GMC of anti-HBs, and a higher proportion of seroconversion and high-level response than the IM20 group did (P < 0.05). Better immune responses were observed in the IM60 group, especially for those aged or in the high-frequency hemodialysis population. Conclusion: The high dose 60 µg recombinant hepatitis B vaccines elicited stronger immune responses than the 20 µg hepatitis B vaccine did among hemodialysis patients. Clinical trial registration: ClinicalTrials.gov, number NCT02963714.